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Shirley Victoria Hodgson6, Heidi C Howard7,8, Jürgen John1, Helena Kääriäinen9, Hülya Kayserili10,
Alastair Kent11, Florian Koerber1, Ulf Kristoffersson12, Mark Kroese13, Celine Lewis14, Georg Marckmann15,
Peter Meyer16,17, Arne Pfeufer18, Jörg Schmidtke19, Heather Skirton20, Lisbeth Tranebjærg21,22
and Wolf H Rogowski*,1,23 for the EuroGentest and ESHG/PPPC Priority Consortium
Given the cost constraints of the European health-care systems, criteria are needed to decide which genetic services to fund
from the public budgets, if not all can be covered. To ensure that high-priority services are available equitably within and across
the European countries, a shared set of prioritization criteria would be desirable. A decision process following the accountability
for reasonableness framework was undertaken, including a multidisciplinary EuroGentest/PPPC-ESHG workshop to develop
shared prioritization criteria. Resources are currently too limited to fund all the beneﬁcial genetic testing services available in the
next decade. Ethically and economically reﬂected prioritization criteria are needed. Prioritization should be based on
considerations of medical beneﬁt, health need and costs. Medical beneﬁt includes evidence of beneﬁt in terms of clinical
beneﬁt, beneﬁt of information for important life decisions, beneﬁt for other people apart from the person tested and the patient-
speciﬁc likelihood of being affected by the condition tested for. It may be subject to a ﬁnite time window. Health need includes
the severity of the condition tested for and its progression at the time of testing. Further discussion and better evidence is
needed before clearly deﬁned recommendations can be made or a prioritization algorithm proposed. To our knowledge, this is
the ﬁrst time a clinical society has initiated a decision process about health-care prioritization on a European level, following the
principles of accountability for reasonableness. We provide points to consider to stimulate this debate across the EU and to serve
as a reference for improving patient management.
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INTRODUCTION
Genetic testing provides multiple beneﬁts to patients and relatives,
both from a clinical and a non-clinical perspective.1,2 The rapidly
expanding availability and application of genetic testing services3–5
indicates that these beneﬁts are increasingly made accessible to patients
throughout Europe. However, ﬁnancial resources within publicly
funded health-care systems are restricted. Although technical improve-
ments are leading to a decrease in laboratory costs per test, the
evidence that genetic tests produce overall savings in health-care
systems is currently weak6 and limited to a minority of tests.7,8 Rather,
the costs of data analysis and storage, interpreting the test results,
counseling services and follow-up care could lead to an increase in the
overall health-care costs associated with genetic testing.9,10 Therefore
decisions have to be made about which tests should be covered by the
public health-care budgets.
To date there is a lack of structured guidance for the decision-
makers on how to give priority to genetic tests within clinical genetic
services. In a Canadian survey, health-care providers reported that
given the absence of coordinated approaches, resource allocation
decisions are often left to local providers of genetic tests.11 It is likely
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that this is also the case in many European health-care systems.12 In
the face of resource constraints, prioritization decisions are likely to be
based on contingencies of daily practice rather than on well-reﬂected
considerations. Also, there is a risk that without a shared set of
prioritization criteria, decision makers may be accused of overprovi-
sion by health-care ﬁnancers or of under-provision of genetic services
by patients. Given this situation, it has been argued that the
development of agreed standards for resource allocation decisions
based on sound medical, economic and ethical considerations would
be beneﬁcial for both decision-makers and those who potentially
beneﬁt from health care.13
The question as to how health-care services should be given priority
has a long history of debate within the literature. The challenge for
prioritizing genetic tests is to determine a set of criteria that can be
applied to rank order different tests according to their relative priority.
Even if theoretical and empirical work on such criteria is available in
the literature,14,15 it has been argued that reasonable people may still
disagree about which criteria should be applied and, if more than one
criterion applies, about the relative weight they should receive.16
Therefore, these issues have to be resolved in a fair decision procedure
to obtain legitimate guidance. A widely cited framework of procedural
fairness is ‘accountability for reasonableness’ (A4R).17 The following
paper describes the results of a consensus process that has been
organized according to this framework. The aim of the process was to
develop a shared set of criteria and considerations for prioritizing
genetic tests which can be used on a regional and local level of decision
making in the absence of clearly deﬁned national prioritization
guidance.
MATERIALS AND METHODS
According to Daniels and Sabin,16,17 a decision process complies with A4R if it
meets the following four conditions: relevance, publicity, revision and appeal
and enforcement. The following section illustrates how these conditions were
addressed during this decision process about a general prioritization framework
for genetic services. Brieﬂy, the process was based on ﬁve steps (see Figure 1):
(1) identifying intuitively plausible and practically relevant prioritization
criteria; (2) developing a theoretical framework for reasonable prioritization;
(3) establishing evidence about tentative weights these prioritization criteria
should have; (4) stakeholder and expert deliberation about the steps (1)–(3);
and (5) website publication of the results to allow for revision and appeal. The
central part of step (4) was a two-day stakeholder and expert workshop (from
28 to 29 November 2012) with 25 participants which was part of the activities
conducted within EuroGentest (www.eurogentest.org).
Relevance
The relevance condition of A4R requires that the prioritization rests on
evidence, reasons and principles that fair-minded people can agree are relevant
for patient care under resource constraints.17 Hence as a starting point,
interviews with clinicians and patient representatives were conducted to elicit
criteria which are relevant to the most important stakeholders. To obtain a
general overview of the patient perspective, we focused on communicating with
patient representatives rather than patients themselves.15 Furthermore, an
explorative literature review assessed normative frameworks relevant for
prioritizing genetic services in a reasonable and fair manner14 and a theoretical
prioritization framework was developed. The criteria which appeared most
relevant were operationalized and weighted within a discrete-choice experiment
(DCE).15,18 The statistically signiﬁcant impact of the criteria described in the
DCE served as a conﬁrmation of the criteria’s relevance. To prepare for the
discussion, the criteria were shared with the workshop participants prior to the
meeting, alongside with a survey regarding the participants’ views and
experiences with prioritization practice.
Scientiﬁc publication of this document also contributes to the relevance
criterion, because it facilitates further debate in a transparent way.
Publicity
The publicity condition requires that the rationales for resource allocation
decisions are accessible to the relevant stakeholders.17 It was assumed that
health-care providers and patients are the most important stakeholders for the
vertical prioritization of budgets for genetic services. Further stakeholders
include health-care funders, regulatory agencies, industry representatives and
the general population. Information about this prioritization activity toward
these stakeholders was provided through different channels such as relevant
newsletters, websites (eg the EuroGentest website) and personal communica-
tions to the relevant stakeholders. Furthermore, it was presented at the
EuroGentest General Assembly March 2013 in Prague and at the Annual
Conference of the European Society of Human Genetics (ESHG) June 2013
in Paris.
Revision and appeal
Those affected by a decision should have the chance to challenge it on the basis
of relevant arguments that have not been considered duly during the original
decision-making process.17 To ensure that as many rationales as possible were
considered during the workshop, a broad range of expertise (clinical genetics,
molecular genetics, economics, ethics, public health and sociology) and various
stakeholders (clinicians, patient representatives, health technology assessment
agencies and neutral experts who can contribute views from the informed
general population) were involved in the workshop and its preparation (see
Supplementary Appendix Table 1 for a list of participants). They also included
members of the Public and Professional Policy Committee of the ESHG.
Unanimous assent was reached, ensuring that the value judgments of all the
included stakeholders were accounted for.
Preliminary versions of this recommendation statement were shared for
comments and revisions among the workshop participants as well as on the
website of the ESHG and EuroGentest. A broad range of stakeholders were
contacted by email and invited to comment. The document was then submitted
to the standard process of ESHG recommendations including approval by the
ESHG board. The preliminary version and all written stakeholder comments
made before the ﬁnal version are available from the ﬁrst author upon request.
Enforcement
Apart from the conditions of publicity, relevance and revision and appeals, A4R
requires that appropriate regulation is in place to ensure that the prioritization
decisions comply with these conditions. To facilitate enforcement for this rather
singular process of developing a general decision framework for prioritization
decisions, this study draws upon the standard process for documents to
formally become ESHG statements. These processes always have to include
website publication (publicity), open discussion on the website (relevance) and
incorporation of comments (revisability/appeals). The following sections
outline the results of the consensus process on prioritization criteria for
genetic tests.
Identifying relevant
prioritization criteria: 
Literature review and explorative
interviews 
Selection of appropriate
decision framework:  
Establishing a theoretical
framework for prioritizing
genetic tests  
Collection of empirical
evidence:  
Discrete choice
experiment
Stakeholder deliberation:
Prioritization workshop
28-29th November 2012 
Commenting Phase:
Consented document was
made publically available 
Figure 1 Overview of prioritization process.
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RESULTS
Scope and context of prioritizing genetic tests
In the following, ‘genetic tests’ refer to genetic services as a whole. This
includes, ﬁrst, the analysis of human DNA, RNA, chromosomes,
proteins or certain metabolites to detect heritable disorders or
treatment responses (the laboratory testing process). Second, it
includes the process of analyzing and interpreting the tests result.
Third, it includes informing the patient about the test results and the
implications for his or her life, a procedure which may differ among
diagnoses and may include genetic counseling. We excluded trans-
generational aspects of genetic testing (eg pre-implantation and
prenatal testing) as these tests involve a range of very speciﬁc issues
including concerns about eugenics that are discussed elsewhere. Also,
population screening programs were excluded as they are expected to
undergo separate kinds of prioritization considerations in comparison
with other public health programs.
Prioritization should be preceded by efforts to improve the
efﬁciency of care. This includes a focus on tests with both sufﬁcient
test performance and validity, that is, the sensitivity and speciﬁcity of
the test and scientiﬁc validity for the analysis, and on information
regarding the clinical implications of the test result. Conﬁdence in the
test’s performance and the implication of its results is particularly
relevant for multifactorial diseases where it is often unclear how the
discoveries can be used to improve the patient treatment as the
positive and negative predictive values of the test results are small,
while the conﬁdence intervals of the prediction are wide. Recently, the
ESHG made a recommendation against the use of tests for multi-
factorial conditions, where evidence of the clinical impact on patient
beneﬁt are not sufﬁciently met.19
Prioritization of genetic tests here is understood as placing tests into
a rank order or into rank-ordered categories. Prioritization of genetic
services (and, consequently, exclusion of others from public funding)
can occur in different ways. For example, local decision-making
committees of health-care providers may determine whether a testing
service is provided or excluded from provision at the expense of the
existing budget. Alternatively, prioritization can be the basis to limit
the scope of a test (eg testing is only provided for the most frequent
pathogenic variants rather than the whole gene). Furthermore, it can
used to assign services to different priority categories which determine
the place of the testing service on a waiting list, so that individuals who
seek testing may wait longer or shorter periods of time depending on
the anticipated suffering from avoidable disease and uncertainty. It is
important to realize that prioritization is not a one-way road to
limiting services: Tests with a high priority should be made available to
all individuals who might beneﬁt from it.
This prioritization activity focuses on the efﬁcient and fair allocation
of collectively funded resources (eg taxes or contributions to statutory
health insurance) on a regional or local level (eg to inform decisions
by commissions on the management of genetics services of a hospital’s
genetics unit which has a ﬁxed budget to spend). As reimbursement
rules typically differ across health-care systems, this guideline can only
serve as a complementary decision aid and cannot replace existing
national coverage and prioritization standards.
These points to be considered are intended for situations where not
all desirable genetics services that are technically available can be
offered to all patients who may need them because of a lack of funding
(eg, because there are too few geneticists to see all patients or because
there is a lack of funding to pay the lab test).
Relevant criteria for prioritizing genetic tests
The workshop participants and commentators on this document
agreed that medical beneﬁt, health need and costs (see Table 1) should
be taken into consideration for prioritizing genetic services. In general,
it was considered desirable to operationalize and weight these criteria
using empirical methods, so that genetic tests can be ranked in a
scientiﬁcally reﬂected manner. However, a number of points have to
be considered before these criteria can be used for prioritizing
genetic tests.
Medical beneﬁt
Patients can derive many beneﬁts from genetic testing. When
conducting a beneﬁt assessment, it is important not only to include
the positive effects but also to weight beneﬁts against the harms that
might be associated with the genetic test.1
Clinical beneﬁt for the tested individual
From a medical perspective, the distinction between a test where an
effective clinical treatment or prevention options exist and a test where
the disease progression cannot be altered with preventive measures or
by treatment is of substantial importance. Detecting an individual with
a condition for which medical interventions are available should have
higher priority than identifying an individual with a similar risk of a
condition with no evidence that the disease can be prevented or that
its course can be altered in a favorable way.
In some cases, particularly for rare disorders and for long-term
beneﬁts, the evidence for the clinical beneﬁt might be hard to
establish. Also, individual behavior patterns need to be accounted
for when assessing the beneﬁt of a genetic test. Although there might
be a beneﬁt from the genetic test per se, some individuals might not
have it because they do not accept the next step of treatment or
prevention or just do not want to know. The clinical beneﬁt of genetic
testing also includes reduction in anxiety if a close relative of a patient
with a severe hereditary disease is diagnosed not to carry the mutated
allele, and no longer needs clinical follow-up.
Non-clinical beneﬁt for the tested individual
Similar to some other kinds of diagnostics, genetic testing can also
provide large beneﬁts that are not covered by existing measures of
clinical beneﬁt. An integrated part of the clinical care is to provide
individuals with a more accurate prognosis concerning life span and
quality of life. Although there might not be a treatment or prevention
option available, the diagnosis itself may, in some cases, enable the
individuals and families to plan their lives in light of what is known
about the particular condition. This may be the case with Huntington
disease, where the test result provides information that could help to
make decisions even if it does not, in itself, alter the natural course of
the condition. Such non-clinical consequences are frequently labeled
as patient empowerment,20 because they enable the patients to get a
better mental and emotional control over their health and health care,
and account for other aspects of their lives which are inﬂuenced by
their current and future health status. These consequences should also
be considered in appraising the priority of a genetic test. Non-clinical
beneﬁts may also arise from information which neither leads to any
action of clinicians nor of patients. Also here, further evidence is
needed and the priority that tests with such beneﬁts should have needs
to be determined.
Beneﬁts for family members
The beneﬁts from genetic testing may also apply to individuals other
than the index patient. Cascade testing of close relatives of an
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individual with a genetic condition helps to effectively identify
additional carriers of pathogenic variants. For example, in the case
of Lynch syndrome, testing is conducted not only for the beneﬁt of the
index case but also for his or her relatives. This is because carriers can
choose to undertake increased colonoscopic surveillance which
improves their expected health outcomes.21,22
Also, non-clinical beneﬁts may apply to the relatives of an index
case if the disease risk of a relative is established. If in a family with
suspected Lynch syndrome a pathogenic variant was detected so that
relatives can undergo testing, some would experience relief from not
carrying the familial variant and removal of the need for regular
invasive surveillance. However, particularly in the case of tests because
of non-clinical beneﬁts for family members, relevant trade-offs with
concerns for privacy or the right not to know may have to be taken
into consideration.
Likelihood of disease
One indicator of the size of beneﬁt which can be obtained by a genetic
test is the patient’s a-priori risk of being tested positive for the
condition. Identifying individuals at increased risk is of key impor-
tance as testing high-risk groups improves the performance of the test
in terms of the cases detected. Therefore, it seems to be justiﬁed to give
priority to individuals who are likely to be at substantially greater risk
of having a condition than others in the population (in particular,
close relatives). Also, high-risk subpopulations can be considered of
higher priority for genetic testing than individuals in populations with
lower pathogenic variant prevalence.
Particularly for predictive/presymptomatic testing, it should be
noted that ‘likelihood of disease’ refers to the risk of the phenotype.
Therefore, incomplete penetrance, that is, a reduced probability of
overt symptoms in people who have the underlying genetic defect,
directly affects the risk assessment. Testing an individual with an
elevated risk of a low-penetrance condition might be of lower priority
than testing an individual with an equivalent risk of a pathogenic
variant with a full-penetrance condition. Also, it needs to be
considered that a familial aggregation in presence of a pathogenic
variant might confer a higher individual risk for a relative to develop
the condition than in the absence of a positive family history.
Table 1 Points to consider for prioritizing genetic tests
Criterion Explanation Selected challenges for measurement and use
Medical beneﬁt
Clinical beneﬁt for tested individual Tests where, based on the results, effective clinical treatment or
prevention options exist, should be of higher priority than tests
without effective interventions.
For rare diseases and long-beneﬁt, evidence frequently is weak.
Individual behavior patterns (eg whether the treatment would be
pursued) need to be accounted for to establish the beneﬁt of a
genetic test.
Non-clinical beneﬁt for tested individual Consideration of beneﬁt also should include health-related infor-
mation by itself which may assist individuals and families in
planning their life.
There is a need for more scientiﬁc evidence about the beneﬁt for life
decision making (‘empowerment’) incurred by different genetic tests.
It is unclear how non-actionable information should be accounted for.
Beneﬁt for family members Consideration of beneﬁt also should include beneﬁts for the family
members.
Also, the non-clinical beneﬁts may apply to relatives.
Particularly for tests because of non-medical beneﬁts, trade-offs with
concerns for privacy or the right not to know may be relevant.
Likelihood Tests for patients with high a-priori risk of developing the disease
(eg high-risk populations or even ﬁrst-degree relatives) should be
of higher priority than tests for patients with low a-priori risk.
Incomplete penetrance, that is, a low probability of overt symptoms
needs to be incorporated in risk assessment.
High-risk individuals may be more likely to be detected as genetic
cases in clinical practice than medium-risk individuals.
Time window It may be that the beneﬁt from a test can only be obtained within
a ﬁnite time window.
Criterion likely to be of higher relevance for a local perspective which
also includes management issues than from a health-care system
perspective.
Health need
Severity Tests for conditions with a severe impact on the patient’s health
should be of higher priority than tests for comparatively mild
diseases.
Severity can be expressed in reduced life expectancy or in reduced
health related quality of life. Methodological details of measuring
severity need to be considered because they can cause concerns, for
example, if QALYs are used.
Progression Tests for conditions which may already have developed silently or
even overtly in the tested individual should be of higher priority
than tests in healthy individuals before the onset of disease.
Needs to be applied in context-dependent manner:
At a certain stage of progression clinical signs and symptoms may be
more accurate and make genetic testing obsolete.
May be inversely related to medical beneﬁt if beneﬁt primarily arises
from prevention in healthy or presymptomatic carriers.
Costs
Costs Tests with lower costs (and, thus, less other tests displaced)
should be of higher priority than high-cost tests.
Consideration of costs should include savings elsewhere in health-care.
Further evidence from well-designed economic evaluations are needed.
Costs should not be the dominant but only one criterion among others.
Weighting the criteria Typically, tests differ across different criteria simultaneously so that the criteria need to be weighted. A score based on empirical methods of
measuring and weighting the criteria would be desirable. However, currently, it is too premature for such quantitative ranking algorithm, for
example, because of too limited evidence about whether the criteria are met and unresolved questions about which value judgments should
be incorporated into the empirical analysis.
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This might, for example, be the case for pathogenic variants in the
CHEK2 gene and breast cancer.23
Furthermore, it may need to be considered that population groups
with high pathogenic variant probabilities are more likely to be
recognized as genetic cases in the clinical environment than those
with lower probabilities and therefore will not beneﬁt from special
patient care. Therefore, also this criterion may need to be adapted to
the context.
Time window to obtain beneﬁt
It may be that the beneﬁt from a test can only be obtained within a
ﬁnite time window. This is the case if there is a restricted time in
which the clinical reaction on a positive diagnosis can still be effective.
For example, in a newborn at risk of an inherited error of metabolism
who (in the case of a positive diagnosis) would immediately need a
special diet there is a restricted time window in which testing can be
conducted. Tests may be less urgent if therapy can be started
somewhat later without negative effects on the course of the disease.
Timing is, therefore, also a relevant aspect for priority setting.
Health need
Besides the medical beneﬁt, also health need should be considered
which can exist independently of whether a treatment is available to
improve the patient’s health. Two aspects of health need appeared
most important for prioritizing genetic tests.
Severity of the disease
One important aspect is the impact that the condition targeted by the
test has on the patient’s health. It can be assumed that individuals at
risk of a severe condition are worse off than those at risk of a milder
condition. Therefore testing for severe conditions should be assigned
higher priority than testing for milder conditions. It was generally
agreed that the severity of a genetic condition can be expressed in
terms of reduced life expectancy, in reduced health related quality of
life or a combination of these two. While some diseases could lead to
greatly reduced life expectancy, other conditions can confer long-term
disabilities. To compare these diseases, ‘severity’ needs to be measured.
However, methodological details of measuring severity can cause
concerns; for example, concerns that have been expressed against the
use of quality-adjusted life years (QALYs) if this metric was used. Also,
it needs to be determined to what extent ‘severity’ should be based on
objective measures or on the subjective patient experience.
Progression of disease
Another aspect of health need that should be considered is how
immediate the potential health loss is at the time of testing. This can
be estimated by the extent to which the condition may already have
progressed in the tested individual. The more advanced a disease is
likely to be, given the patient’s age and potential symptoms, the higher
the priority of the test.
However, this can be highly context-sensitive; beyond a certain stage
of progression, clinical signs and symptoms may be more accurate and
make genetic testing redundant. Also, health need in terms of
progression may be negatively correlated with health beneﬁt: in the
case of hereditary cancer, for example, genetic tests are likely to be
most important for healthy individuals because prevention is most
effective at early stages of cancer development.
Costs
Conducting one test in a situation of resource scarcity where not all
tests can be funded implies that there are other tests which are omitted
and the beneﬁts of these other tests are thus forgone. Therefore, also
the resources consumed by a genetic test (and thus unavailable for
alternative tests) should be considered.
Ideally, costs should be considered from a societal or at least a
health-care system perspective, including all costs that are associated
with a genetic testing service (eg counseling, follow-up testing and
treatment). Also beneﬁts should ideally be considered at a similar level.
From a societal perspective, costs may be much higher than for the
genetic test alone, but they may also come with cost savings elsewhere
in the health-care system or society, for example, owing to disease
prevention. Also, early diagnosis of the condition could result in costs
savings because patients would not continue seeing other doctors and
undergo other tests that incur costs to the health system. The test
result that an individual is not a carrier might also lead to cost savings
if otherwise indicated measures and interventions are not
implemented.
However, to be conﬁdent about the overall additional costs or cost
savings, well-designed health economic evaluations are necessary.7,9
In practice, information about resource consumption over the whole
care process is likely to be limited so that it may be necessary to restrict
the assessment of costs to the total costs from a health-care provider
perspective, including only the relevant scarce budgets for laboratory
testing and counseling.
To explore the opportunity costs of the current service patterns,
discussions about prioritization should attempt to incorporate infor-
mation about the types of resource constraints and the types of tests
currently withheld due to these resource constraints. The priority of
these tests forgone can serve as one qualitative benchmark for deciding
whether a new test should be funded from limited resources.
The overall budget impact of a genetic test is also relevant such that,
the higher the budget impact, the better the evidence of the
aforementioned relevant criteria should be in order to support its
coverage. This is also to avoid discrimination against rare diseases
which may have less evidence available but also less budget impact.
Establishing the relative importance of criteria
Genetic tests typically differ by more than one of these criteria
simultaneously. Some testing situations might be clearly dominated
by others, for example, in the case of testing a ﬁrst-degree relative for a
severe and treatable condition compared with testing someone without
a family history for a mild and untreatable condition. However, most
testing situations are likely to be less obvious. The resulting order of
priority then depends on the weights given to each of these criteria.
Generally, empirical methods such as DCEs can be used to appraise
the relative importance of one criterion over the other.15 Results from
the preparatory DCE among patients and clinicians indicated that
participants attached particularly high value to a proven medical
beneﬁt of the test, high risk of having the disease and low costs of the
test.15 The ﬁeld of organ transplantation is an example where
sophisticated algorithms have been developed and are used for
allocating a scarce resource.24
At the current point in time however, it is premature to propose
such an algorithm for genetic tests. This is, for example, because the
evidence regarding the extent to which the criteria above are met is
still too weak to allow for a valid quantitative ranking of tests. Also,
fair and reasonable prioritization is highly context-speciﬁc and may
depend on multiple further issues for which it is currently unclear how
they can best be incorporated into or addressed alongside the use of
such a prioritization algorithm.
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How to use this prioritization framework
At this point in time, the public discussion about priority setting in
Europe is still at an early stage and there is neither consensus about the
most appropriate ethical frameworks nor the economic tools and their
practical implementation. Moreover, genetic services are currently
undergoing tremendous technological change and the decision con-
texts are highly heterogeneous across European health-care systems.
Also, it is hardly possible to predict which further points have to be
considered in future. Therefore, it is premature to give clear
recommendations about how genetic tests are to be prioritized.
Instead, these criteria can be used for three purposes; ﬁrst, they
provide points to consider when prioritization decisions have to be
made, for example, at meetings on an annual basis when existing
procedures for patient management are reviewed. Not only the criteria
per se but also the procedural framework of A4R can provide a
valuable orientation of fair and reasonable decisions about prioritizing
genetic services. Second, they can serve as a starting point for the
further development of quantitative approaches such as ranking lists
established on the basis of DCE results. Third, these points to consider
can serve as a valuable basis for discussing current priorities for genetic
care in order to identify which services are indispensable and where
there is room for improvement regarding equitable access to high-
priority services. Going through the exercise of matching past
decisions against the suggested set of criteria within a team of
clinicians or regional administrators of public health funds can also
have a positive impact on the consistency of allocation decisions, even
if it is unlikely (and not necessarily desirable) that all subjectivity and
the need for prudential judgment can be eliminated.
DISCUSSION
Throughout Europe, clinicians are faced with resource constraints and
the problem of implicit prioritization of health-care services. Although
whole genome sequencing techniques lead to steadily decreasing
laboratory costs, the increasing volume of tests as well as the costs
associated with the efforts and expertise to interpret complex test
results could lead to an overall increase in health-care expenditure.10
Therefore prioritization criteria similar to those discussed above might
still be needed if genetic tests based on whole genome sequencing are
used on a larger scale in clinical practice. Both, the new types of
diagnostics and the increasing availability of new interventions is likely
to drive the need for priority setting.
To our knowledge, this is the ﬁrst time a clinical society has
responded actively to this challenge on a European level. The decision
process resulted in points to consider for prioritizing genetic tests. As
it is currently premature to develop deﬁnite and structured recom-
mendations, these points to consider are intended to stimulate a
longer process of identifying acceptable prioritization tools. At this
point in time, the results from this project are therefore just the ﬁrst
step toward a more harmonized and equitable provision of high-
priority genetic services.
Implications for future prioritization activities
Genetic exceptionalism for prioritization?. This study developed an
approach for vertical prioritization of genetics services only. Generic
measures that can inform prioritization between a range of medical
technologies often rely on generic concepts such as costs per QALYs.
Although such generic concepts can also be used to assess the medical
beneﬁt of a genetic test, they are of limited sensitivity to the multi-
faceted beneﬁts and relevant issues in the provision of genetic tests.
Also, the applicability of condition-neutral frameworks is limited if
budgets are assigned to different clinical areas, such as genetic services,
and prioritization has to take place within these budgets. This
framework may provide a more acceptable alternative because it
accounts for speciﬁc attributes of genetic tests.
There are also genetic services which are integrated into other
clinical areas such as genetic screening programs which are funded
from public health service budgets. Here, it is more likely that their
beneﬁts and costs have to be balanced against the beneﬁts and costs of
very different alternatives. Therefore, the use of more condition-
neutral tools is more likely to be applicable. Nevertheless, maximiza-
tion of health outcomes like QALYs is unlikely to be considered
acceptable by all participating stakeholders.25 This study can help to
identify relevant points that should also be considered. Criteria of
health need, such as the potential progression of disease or beneﬁt in
terms of information for life decision making without tangible health
beneﬁt is likely to be relevant for other diagnostics as well.
Using accountability for reasonableness for prioritization. To our
knowledge, this is also the ﬁrst time an international organization
like the ESHG has speciﬁcally applied the widely cited ‘accountability
for reasonableness’ framework17 to improve the legitimacy of the
recommendations for priority setting.
This normative framework is sufﬁciently generic to allow for very
different ways of implementation. In this context, it appeared very
consistent with standards of good scientiﬁc practice. This case study
may therefore also serve as an example for prioritization processes in
other clinical areas.
Implications for further research
Genetic testing can provide large clinical and non-clinical beneﬁts for
the tested individuals and their family members, both in case of a
positive and a negative test result. However, it is very unlikely that in
near future for all or most genetic tests a statistically signiﬁcant
establishment of this beneﬁt can be achieved. Particularly for beneﬁts
that are not strictly clinical (yet still related to health, such as anxiety
and so on), the evidence is still weak. Instruments for measuring this
type of beneﬁt are needed in a context of scarce resources and
evidence-based medicine where technologies without good evidence of
beneﬁt may be candidates for exclusion from coverage.
Also, there is little evidence about the total effects and costs of
genetic services from a health-care system perspective–a recent review
of economic evaluations of genetically targeted interventions has
concluded that the use of genetic tests for personalizing medicine
does not per se provide high or low value for money. Instead, the cost-
effectiveness of genetic tests largely depends on how genetic tests are
used in the care process.26 In the face of falling test costs and improved
means of prevention, there may be many applications where whole
genome sequencing techniques are not only beneﬁcial for patients but
also highly cost-effective or even cost-saving. More health economic
evidence is needed to identify these applications and more methodo-
logical work is needed to validate projected effects and costs alongside
their use in practice.
The lack of evidence for a criterion should not necessarily lead to
exclusion of a test from coverage. This is particularly true for very-rare
diseases, where a lower threshold of evidence as part of the evaluation
process might be acceptable because the number of patients is too
small to conduct reliable clinical studies. A future challenge that needs
to be resolved is therefore, how the evidence gap can be ﬁlled in a
reasonable and fair manner.
Furthermore, this study revealed the need for standards regarding
the speciﬁcation and operationalization of the prioritization criteria.
For example, ‘severity of disease’ can be measured according to
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different concepts which could result in different rank orders.27 Also,
further work is needed to explore the applicability of this framework
for prioritizing genetic tests in other medical specialties.
Although A4R is highly cited in the literature, there is still little
known about its impact on decisions and its acceptance in health-care
practice. First evidence suggests that transparency and participation
does indeed increase the reasonableness of decision criteria.28
Further research is necessary, for example on the impact of decision
outcomes if other stakeholders are included which could be assessed
within further workshops. Also, the acceptability of the ﬁnal results
from this guideline as well as its uptake and impact of use in health-
care practice needs to be assessed further.
CONCLUSION
Explicit, fair and reasonable priority setting of health-care resources in
Europe is still at an early stage. The results from this study provide
important points to consider for prioritizing genetic tests and highlight
issues that need further development.
Within this study we provide results from a decision process
oriented at the A4R principles about prioritization criteria for genetic
testing services. Key criteria were evidence of clinical beneﬁt for the
individual being tested, beneﬁt for planning one’s life, beneﬁt for other
persons and timing to obtain the beneﬁt, the likelihood of disease or
beneﬁt, severity and progression of the disease and the costs of the test.
These criteria should not be seen as ﬁxed or ﬁnal, but rather as a
starting point for further discussions toward a more harmonized and
considered approach to priority setting for genetic services across
the EU.
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